Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year to $199.9 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.92 per share was 8.8% above analysts’ consensus estimates.Read More
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
